Shanghai Fosun Pharmaceutical…announced that its subsidiary Avanc Pharmaceutical Co., Ltd. has secured National Medical Products Administration (NMPA) approval for a new indication of fovinaciclib, a next‑generation CDK4/6 inhibitor